{"file_path": "/Users/sz904/Desktop/11711/LTI_Neural_Navigator/data/2024-02-26/chunk_paper_txt/Yiming_Yang_MRI_Features_for_Predicting_Microvascular_Invasion_and_Postoperative_Recurrence_in_Hepatocellular_Carcinoma_Without_Peritumoral_Hypointensity_chunk_6.txt", "num_qa_pairs": 10, "qa_list": [{"question": " What does MVI stand for in the text?", "answer": " MVI stands for microvascular invasion.", "ref_chunk": "MVI, microvascular invasion; Gd-EOB-DTPA, gadolinium ethoxybenzyl diethylene- triamine pentaacetic acid; OATP, organic anion-transporting polypeptide; HBP, hepatobiliary phase; WBC, white blood cell count; RBC, red blood cell count; HB, hemoglobin; PLT, platelets; PT, prothrombin time; INR, international normalized ratio of prothrombin; APTT, activated partial thromboplastin time; FIB, fibrinogen; AST, aspartate amino- transferase; ALT, alanine transaminase; ALB, albumin; GLB, globulin; ALP, alkaline phosphatase; GGT, gamma- glutamyl transferase; TBIL, total bilirubin; Cr, creatinine; AFP, alpha-fetoprotein; CTP, Child-Turcotte-Pugh stage; MELD, model for end-stage liver disease score; AASLD, American association for the study of liver disease; RFS, recurrence-free survival; ROC, receiver operating characteristic; AUROC, area under ROC curve; OR, odds ratio; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value; HR, hazard ratio. 1606 Journal of Hepatocellular Carcinoma 2023:10 https://doi.org/10.2147/JHC.S422632 DovePress Powered by TCPDF (www.tcpdf.org) Powered by TCPDF (www.tcpdf.org) Dovepress Chen et al Data Sharing Statement The datasets used and/or analyzed in this study are available from the corresponding authors on reasonable request. Ethics Approval and Informed Consent The studies involving human participants were reviewed and approved by the ethics committee of the Second Affiliated Hospital of Guangzhou University of Chinese Medicine (BE2022-226). The study was completed in accordance with the Declaration of Helsinki, and all patient data are treated confidentially. The requirement for written informed consent was waived by the Institutional Review Board in view of the retrospective observational nature of the research. Before Gd- EOB-DTPA enhanced MRI and curative hepatic resection, subjects received full information about indications, risks, and alternatives and then signed the written informed consent. Acknowledgments We thank Liwen Bianji (Edanz) for editing the English language in the draft of this manuscript. Author Contributions Conceptualization, Zhiyuan Chen, Xiaohuan Li, and Yupin Liu; design, Zhiyuan Chen, Dongjing Zhou, and Yupin Liu; Resources, Zhiyuan Chen, Yan Zhang, and Yupin Liu; execution, Xiaohuan Li, Yu Zhang, Yiming Yang, Yu Yang, and Shuping Zhang; acquisition of data, Xiaohuan Li, Yu Zhang, Yiming Yang, Yan Zhang, and Yu Yang; Formal Analysis, Zhiyuan Chen, Xiaohuan Li, Yan Zhang, and Dongjing Zhou;; Writing \u2013 Original Draft, Zhiyuan Chen, Xiaohuan Li, Yu Zhang, Yiming Yang, Yan Zhang, Yu Yang, and Shuping Zhang; Writing \u2013 Review & Editing, Zhiyuan Chen, Dongjing Zhou, and Yupin Liu. All authors made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; took part in drafting the article or revising it critically for important intellectual content; agreed to submit to the current journal; gave final approval of the version to be published; and agree to be accountable for all aspects of the work. Funding This work was funded by the Traditional Chinese medicine research project of the Second Affiliated Hospital of Guangzhou University of Chinese Medicine (YN2019QL09, ZY2022YL06). Disclosure The authors report no conflicts of interest in this work. References 1. Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400(10360):1345\u20131362. doi:10.1016/S0140- 6736(22)01200-4 2. Calderaro J, Seraphin TP, Luedde T, Simon TG. Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma. J Hepatol. 2022;76(6):1348\u20131361. 3. Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77(6):1598\u20131606. doi:10.1016/j.jhep.2022.08.021 4. Erstad DJ, Tanabe KK. Prognostic and therapeutic implications of microvascular invasion in hepatocellular carcinoma. Ann Surg Oncol. 2019;26 (5):1474\u20131493. doi:10.1245/s10434-019-07227-9 5. Beaufr\u00e8re A, Caruso S, Calderaro J, et al. Gene expression signature as a surrogate marker of microvascular invasion on routine hepatocellular carcinoma biopsies. J Hepatol. 2022;76(2):343\u2013352. doi:10.1016/j.jhep.2021.09.034 6. Wu Y, Zhu M, Liu Y, Cao X, Zhang G, Yin L. Peritumoral imaging manifestations on Gd-EOB-DTPA-enhanced MRI for preoperative prediction of microvascular invasion in hepatocellular carcinoma: a systematic review and meta-analysis. Front Oncol. 2022;12:907076. doi:10.3389/ fonc.2022.907076 7. Hong SB, Choi SH, Kim SY, et al. MRI features for predicting microvascular invasion of hepatocellular carcinoma: a systematic review and meta-analysis. Liver Cancer. 2021;10(2):94\u2013106. doi:10.1159/000513704 8. Rhee H, Cho ES, Nahm JH, et al. Gadoxetic acid-enhanced MRI of macrotrabecular-massive hepatocellular carcinoma and its prognostic implications. J Hepatol. 2021;74(1):109\u2013121. doi:10.1016/j.jhep.2020.08.013 9. Kang HJ, Kim H, Lee DH, et al. Gadoxetate-enhanced MRI features of proliferative hepatocellular carcinoma are prognostic after surgery. Radiology. 2021;300(3):572\u2013582. doi:10.1148/radiol.2021204352 10. Elsayes KM, Kielar AZ, Chernyak V, et al. LI-RADS: a conceptual and historical review from its beginning to its recent integration into AASLD clinical practice guidance. J Hepatocell Carcinoma. 2019;6:49\u201369. doi:10.2147/JHC.S186239 Journal of Hepatocellular Carcinoma 2023:10 https://doi.org/10.2147/JHC.S422632 1607 DovePress Powered by TCPDF (www.tcpdf.org) Powered by TCPDF (www.tcpdf.org) Chen et al Dovepress 11. Kim WR, Mannalithara A, Heimbach JK, et al. MELD 3.0: the model for end-stage liver disease updated for the modern era. Gastroenterology. 2021;161(6):1887\u20131895.e4. doi:10.1053/j.gastro.2021.08.050 12. Benchoufi M, Matzner-Lober E, Molinari N, Jannot AS, Soyer P. Interobserver agreement issues in radiology. Diagn Interv Imaging. 2020;101 (10):639\u2013641. doi:10.1016/j.diii.2020.09.001 13. He T, Zou J, Sun K, et al. Global research status and frontiers on microvascular invasion of hepatocellular carcinoma: a bibliometric and visualized analysis. Front Oncol. 2022;12:1037145. doi:10.3389/fonc.2022.1037145 14. Bai S, Yang P, Xie Z, et al. Preoperative estimated risk of microvascular invasion is associated with prognostic differences following liver resection versus radiofrequency ablation for early hepatitis b virus-related hepatocellular carcinoma. Ann Surg Oncol. 2021;28(13):8174\u20138185. doi:10.1245/ s10434-021-09901-3 15. Lee S, Kang TW, Song KD, et al. Effect of microvascular invasion risk on early recurrence of hepatocellular carcinoma after surgery and radiofrequency ablation. Ann Surg. 2021;273(3):564\u2013571. doi:10.1097/SLA.0000000000003268 16. Meng XP, Tang TY, Ding ZM, et al. preoperative microvascular invasion prediction to assist in surgical plan for single hepatocellular carcinoma: better together with radiomics. Ann Surg Oncol. 2022;29(5):2960\u20132970. doi:10.1245/s10434-022-11346-1 17. Zhang X, Li J, Shen F, Lau WY. Significance of presence of microvascular invasion in specimens obtained after surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol. 2018;33(2):347\u2013354. doi:10.1111/jgh.13843 18. Zhang L, Yu X, Wei W, et al. Prediction of HCC microvascular invasion with gadobenate-enhanced MRI: correlation with pathology. Eur Radiol. 2020;30(10):5327\u20135336. doi:10.1007/s00330-020-06895-6 19. Jiang H, Wei H, Yang T, et al. VICT2 trait: prognostic alternative to peritumoral hepatobiliary phase hypointensity in HCC. Radiology. 2023;307 (2):e221835. doi:10.1148/radiol.221835 20. Kitao A, Matsui O, Zhang Y,"}, {"question": " Which stage was the study completed in accordance with?", "answer": " The study was completed in accordance with the Declaration of Helsinki.", "ref_chunk": "MVI, microvascular invasion; Gd-EOB-DTPA, gadolinium ethoxybenzyl diethylene- triamine pentaacetic acid; OATP, organic anion-transporting polypeptide; HBP, hepatobiliary phase; WBC, white blood cell count; RBC, red blood cell count; HB, hemoglobin; PLT, platelets; PT, prothrombin time; INR, international normalized ratio of prothrombin; APTT, activated partial thromboplastin time; FIB, fibrinogen; AST, aspartate amino- transferase; ALT, alanine transaminase; ALB, albumin; GLB, globulin; ALP, alkaline phosphatase; GGT, gamma- glutamyl transferase; TBIL, total bilirubin; Cr, creatinine; AFP, alpha-fetoprotein; CTP, Child-Turcotte-Pugh stage; MELD, model for end-stage liver disease score; AASLD, American association for the study of liver disease; RFS, recurrence-free survival; ROC, receiver operating characteristic; AUROC, area under ROC curve; OR, odds ratio; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value; HR, hazard ratio. 1606 Journal of Hepatocellular Carcinoma 2023:10 https://doi.org/10.2147/JHC.S422632 DovePress Powered by TCPDF (www.tcpdf.org) Powered by TCPDF (www.tcpdf.org) Dovepress Chen et al Data Sharing Statement The datasets used and/or analyzed in this study are available from the corresponding authors on reasonable request. Ethics Approval and Informed Consent The studies involving human participants were reviewed and approved by the ethics committee of the Second Affiliated Hospital of Guangzhou University of Chinese Medicine (BE2022-226). The study was completed in accordance with the Declaration of Helsinki, and all patient data are treated confidentially. The requirement for written informed consent was waived by the Institutional Review Board in view of the retrospective observational nature of the research. Before Gd- EOB-DTPA enhanced MRI and curative hepatic resection, subjects received full information about indications, risks, and alternatives and then signed the written informed consent. Acknowledgments We thank Liwen Bianji (Edanz) for editing the English language in the draft of this manuscript. Author Contributions Conceptualization, Zhiyuan Chen, Xiaohuan Li, and Yupin Liu; design, Zhiyuan Chen, Dongjing Zhou, and Yupin Liu; Resources, Zhiyuan Chen, Yan Zhang, and Yupin Liu; execution, Xiaohuan Li, Yu Zhang, Yiming Yang, Yu Yang, and Shuping Zhang; acquisition of data, Xiaohuan Li, Yu Zhang, Yiming Yang, Yan Zhang, and Yu Yang; Formal Analysis, Zhiyuan Chen, Xiaohuan Li, Yan Zhang, and Dongjing Zhou;; Writing \u2013 Original Draft, Zhiyuan Chen, Xiaohuan Li, Yu Zhang, Yiming Yang, Yan Zhang, Yu Yang, and Shuping Zhang; Writing \u2013 Review & Editing, Zhiyuan Chen, Dongjing Zhou, and Yupin Liu. All authors made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; took part in drafting the article or revising it critically for important intellectual content; agreed to submit to the current journal; gave final approval of the version to be published; and agree to be accountable for all aspects of the work. Funding This work was funded by the Traditional Chinese medicine research project of the Second Affiliated Hospital of Guangzhou University of Chinese Medicine (YN2019QL09, ZY2022YL06). Disclosure The authors report no conflicts of interest in this work. References 1. Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400(10360):1345\u20131362. doi:10.1016/S0140- 6736(22)01200-4 2. Calderaro J, Seraphin TP, Luedde T, Simon TG. Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma. J Hepatol. 2022;76(6):1348\u20131361. 3. Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77(6):1598\u20131606. doi:10.1016/j.jhep.2022.08.021 4. Erstad DJ, Tanabe KK. Prognostic and therapeutic implications of microvascular invasion in hepatocellular carcinoma. Ann Surg Oncol. 2019;26 (5):1474\u20131493. doi:10.1245/s10434-019-07227-9 5. Beaufr\u00e8re A, Caruso S, Calderaro J, et al. Gene expression signature as a surrogate marker of microvascular invasion on routine hepatocellular carcinoma biopsies. J Hepatol. 2022;76(2):343\u2013352. doi:10.1016/j.jhep.2021.09.034 6. Wu Y, Zhu M, Liu Y, Cao X, Zhang G, Yin L. Peritumoral imaging manifestations on Gd-EOB-DTPA-enhanced MRI for preoperative prediction of microvascular invasion in hepatocellular carcinoma: a systematic review and meta-analysis. Front Oncol. 2022;12:907076. doi:10.3389/ fonc.2022.907076 7. Hong SB, Choi SH, Kim SY, et al. MRI features for predicting microvascular invasion of hepatocellular carcinoma: a systematic review and meta-analysis. Liver Cancer. 2021;10(2):94\u2013106. doi:10.1159/000513704 8. Rhee H, Cho ES, Nahm JH, et al. Gadoxetic acid-enhanced MRI of macrotrabecular-massive hepatocellular carcinoma and its prognostic implications. J Hepatol. 2021;74(1):109\u2013121. doi:10.1016/j.jhep.2020.08.013 9. Kang HJ, Kim H, Lee DH, et al. Gadoxetate-enhanced MRI features of proliferative hepatocellular carcinoma are prognostic after surgery. Radiology. 2021;300(3):572\u2013582. doi:10.1148/radiol.2021204352 10. Elsayes KM, Kielar AZ, Chernyak V, et al. LI-RADS: a conceptual and historical review from its beginning to its recent integration into AASLD clinical practice guidance. J Hepatocell Carcinoma. 2019;6:49\u201369. doi:10.2147/JHC.S186239 Journal of Hepatocellular Carcinoma 2023:10 https://doi.org/10.2147/JHC.S422632 1607 DovePress Powered by TCPDF (www.tcpdf.org) Powered by TCPDF (www.tcpdf.org) Chen et al Dovepress 11. Kim WR, Mannalithara A, Heimbach JK, et al. MELD 3.0: the model for end-stage liver disease updated for the modern era. Gastroenterology. 2021;161(6):1887\u20131895.e4. doi:10.1053/j.gastro.2021.08.050 12. Benchoufi M, Matzner-Lober E, Molinari N, Jannot AS, Soyer P. Interobserver agreement issues in radiology. Diagn Interv Imaging. 2020;101 (10):639\u2013641. doi:10.1016/j.diii.2020.09.001 13. He T, Zou J, Sun K, et al. Global research status and frontiers on microvascular invasion of hepatocellular carcinoma: a bibliometric and visualized analysis. Front Oncol. 2022;12:1037145. doi:10.3389/fonc.2022.1037145 14. Bai S, Yang P, Xie Z, et al. Preoperative estimated risk of microvascular invasion is associated with prognostic differences following liver resection versus radiofrequency ablation for early hepatitis b virus-related hepatocellular carcinoma. Ann Surg Oncol. 2021;28(13):8174\u20138185. doi:10.1245/ s10434-021-09901-3 15. Lee S, Kang TW, Song KD, et al. Effect of microvascular invasion risk on early recurrence of hepatocellular carcinoma after surgery and radiofrequency ablation. Ann Surg. 2021;273(3):564\u2013571. doi:10.1097/SLA.0000000000003268 16. Meng XP, Tang TY, Ding ZM, et al. preoperative microvascular invasion prediction to assist in surgical plan for single hepatocellular carcinoma: better together with radiomics. Ann Surg Oncol. 2022;29(5):2960\u20132970. doi:10.1245/s10434-022-11346-1 17. Zhang X, Li J, Shen F, Lau WY. Significance of presence of microvascular invasion in specimens obtained after surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol. 2018;33(2):347\u2013354. doi:10.1111/jgh.13843 18. Zhang L, Yu X, Wei W, et al. Prediction of HCC microvascular invasion with gadobenate-enhanced MRI: correlation with pathology. Eur Radiol. 2020;30(10):5327\u20135336. doi:10.1007/s00330-020-06895-6 19. Jiang H, Wei H, Yang T, et al. VICT2 trait: prognostic alternative to peritumoral hepatobiliary phase hypointensity in HCC. Radiology. 2023;307 (2):e221835. doi:10.1148/radiol.221835 20. Kitao A, Matsui O, Zhang Y,"}, {"question": " Who reviewed and approved the studies involving human participants?", "answer": " The ethics committee of the Second Affiliated Hospital of Guangzhou University of Chinese Medicine reviewed and approved the studies.", "ref_chunk": "MVI, microvascular invasion; Gd-EOB-DTPA, gadolinium ethoxybenzyl diethylene- triamine pentaacetic acid; OATP, organic anion-transporting polypeptide; HBP, hepatobiliary phase; WBC, white blood cell count; RBC, red blood cell count; HB, hemoglobin; PLT, platelets; PT, prothrombin time; INR, international normalized ratio of prothrombin; APTT, activated partial thromboplastin time; FIB, fibrinogen; AST, aspartate amino- transferase; ALT, alanine transaminase; ALB, albumin; GLB, globulin; ALP, alkaline phosphatase; GGT, gamma- glutamyl transferase; TBIL, total bilirubin; Cr, creatinine; AFP, alpha-fetoprotein; CTP, Child-Turcotte-Pugh stage; MELD, model for end-stage liver disease score; AASLD, American association for the study of liver disease; RFS, recurrence-free survival; ROC, receiver operating characteristic; AUROC, area under ROC curve; OR, odds ratio; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value; HR, hazard ratio. 1606 Journal of Hepatocellular Carcinoma 2023:10 https://doi.org/10.2147/JHC.S422632 DovePress Powered by TCPDF (www.tcpdf.org) Powered by TCPDF (www.tcpdf.org) Dovepress Chen et al Data Sharing Statement The datasets used and/or analyzed in this study are available from the corresponding authors on reasonable request. Ethics Approval and Informed Consent The studies involving human participants were reviewed and approved by the ethics committee of the Second Affiliated Hospital of Guangzhou University of Chinese Medicine (BE2022-226). The study was completed in accordance with the Declaration of Helsinki, and all patient data are treated confidentially. The requirement for written informed consent was waived by the Institutional Review Board in view of the retrospective observational nature of the research. Before Gd- EOB-DTPA enhanced MRI and curative hepatic resection, subjects received full information about indications, risks, and alternatives and then signed the written informed consent. Acknowledgments We thank Liwen Bianji (Edanz) for editing the English language in the draft of this manuscript. Author Contributions Conceptualization, Zhiyuan Chen, Xiaohuan Li, and Yupin Liu; design, Zhiyuan Chen, Dongjing Zhou, and Yupin Liu; Resources, Zhiyuan Chen, Yan Zhang, and Yupin Liu; execution, Xiaohuan Li, Yu Zhang, Yiming Yang, Yu Yang, and Shuping Zhang; acquisition of data, Xiaohuan Li, Yu Zhang, Yiming Yang, Yan Zhang, and Yu Yang; Formal Analysis, Zhiyuan Chen, Xiaohuan Li, Yan Zhang, and Dongjing Zhou;; Writing \u2013 Original Draft, Zhiyuan Chen, Xiaohuan Li, Yu Zhang, Yiming Yang, Yan Zhang, Yu Yang, and Shuping Zhang; Writing \u2013 Review & Editing, Zhiyuan Chen, Dongjing Zhou, and Yupin Liu. All authors made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; took part in drafting the article or revising it critically for important intellectual content; agreed to submit to the current journal; gave final approval of the version to be published; and agree to be accountable for all aspects of the work. Funding This work was funded by the Traditional Chinese medicine research project of the Second Affiliated Hospital of Guangzhou University of Chinese Medicine (YN2019QL09, ZY2022YL06). Disclosure The authors report no conflicts of interest in this work. References 1. Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400(10360):1345\u20131362. doi:10.1016/S0140- 6736(22)01200-4 2. Calderaro J, Seraphin TP, Luedde T, Simon TG. Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma. J Hepatol. 2022;76(6):1348\u20131361. 3. Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77(6):1598\u20131606. doi:10.1016/j.jhep.2022.08.021 4. Erstad DJ, Tanabe KK. Prognostic and therapeutic implications of microvascular invasion in hepatocellular carcinoma. Ann Surg Oncol. 2019;26 (5):1474\u20131493. doi:10.1245/s10434-019-07227-9 5. Beaufr\u00e8re A, Caruso S, Calderaro J, et al. Gene expression signature as a surrogate marker of microvascular invasion on routine hepatocellular carcinoma biopsies. J Hepatol. 2022;76(2):343\u2013352. doi:10.1016/j.jhep.2021.09.034 6. Wu Y, Zhu M, Liu Y, Cao X, Zhang G, Yin L. Peritumoral imaging manifestations on Gd-EOB-DTPA-enhanced MRI for preoperative prediction of microvascular invasion in hepatocellular carcinoma: a systematic review and meta-analysis. Front Oncol. 2022;12:907076. doi:10.3389/ fonc.2022.907076 7. Hong SB, Choi SH, Kim SY, et al. MRI features for predicting microvascular invasion of hepatocellular carcinoma: a systematic review and meta-analysis. Liver Cancer. 2021;10(2):94\u2013106. doi:10.1159/000513704 8. Rhee H, Cho ES, Nahm JH, et al. Gadoxetic acid-enhanced MRI of macrotrabecular-massive hepatocellular carcinoma and its prognostic implications. J Hepatol. 2021;74(1):109\u2013121. doi:10.1016/j.jhep.2020.08.013 9. Kang HJ, Kim H, Lee DH, et al. Gadoxetate-enhanced MRI features of proliferative hepatocellular carcinoma are prognostic after surgery. Radiology. 2021;300(3):572\u2013582. doi:10.1148/radiol.2021204352 10. Elsayes KM, Kielar AZ, Chernyak V, et al. LI-RADS: a conceptual and historical review from its beginning to its recent integration into AASLD clinical practice guidance. J Hepatocell Carcinoma. 2019;6:49\u201369. doi:10.2147/JHC.S186239 Journal of Hepatocellular Carcinoma 2023:10 https://doi.org/10.2147/JHC.S422632 1607 DovePress Powered by TCPDF (www.tcpdf.org) Powered by TCPDF (www.tcpdf.org) Chen et al Dovepress 11. Kim WR, Mannalithara A, Heimbach JK, et al. MELD 3.0: the model for end-stage liver disease updated for the modern era. Gastroenterology. 2021;161(6):1887\u20131895.e4. doi:10.1053/j.gastro.2021.08.050 12. Benchoufi M, Matzner-Lober E, Molinari N, Jannot AS, Soyer P. Interobserver agreement issues in radiology. Diagn Interv Imaging. 2020;101 (10):639\u2013641. doi:10.1016/j.diii.2020.09.001 13. He T, Zou J, Sun K, et al. Global research status and frontiers on microvascular invasion of hepatocellular carcinoma: a bibliometric and visualized analysis. Front Oncol. 2022;12:1037145. doi:10.3389/fonc.2022.1037145 14. Bai S, Yang P, Xie Z, et al. Preoperative estimated risk of microvascular invasion is associated with prognostic differences following liver resection versus radiofrequency ablation for early hepatitis b virus-related hepatocellular carcinoma. Ann Surg Oncol. 2021;28(13):8174\u20138185. doi:10.1245/ s10434-021-09901-3 15. Lee S, Kang TW, Song KD, et al. Effect of microvascular invasion risk on early recurrence of hepatocellular carcinoma after surgery and radiofrequency ablation. Ann Surg. 2021;273(3):564\u2013571. doi:10.1097/SLA.0000000000003268 16. Meng XP, Tang TY, Ding ZM, et al. preoperative microvascular invasion prediction to assist in surgical plan for single hepatocellular carcinoma: better together with radiomics. Ann Surg Oncol. 2022;29(5):2960\u20132970. doi:10.1245/s10434-022-11346-1 17. Zhang X, Li J, Shen F, Lau WY. Significance of presence of microvascular invasion in specimens obtained after surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol. 2018;33(2):347\u2013354. doi:10.1111/jgh.13843 18. Zhang L, Yu X, Wei W, et al. Prediction of HCC microvascular invasion with gadobenate-enhanced MRI: correlation with pathology. Eur Radiol. 2020;30(10):5327\u20135336. doi:10.1007/s00330-020-06895-6 19. Jiang H, Wei H, Yang T, et al. VICT2 trait: prognostic alternative to peritumoral hepatobiliary phase hypointensity in HCC. Radiology. 2023;307 (2):e221835. doi:10.1148/radiol.221835 20. Kitao A, Matsui O, Zhang Y,"}, {"question": " What was waived by the Institutional Review Board in this study?", "answer": " The requirement for written informed consent was waived.", "ref_chunk": "MVI, microvascular invasion; Gd-EOB-DTPA, gadolinium ethoxybenzyl diethylene- triamine pentaacetic acid; OATP, organic anion-transporting polypeptide; HBP, hepatobiliary phase; WBC, white blood cell count; RBC, red blood cell count; HB, hemoglobin; PLT, platelets; PT, prothrombin time; INR, international normalized ratio of prothrombin; APTT, activated partial thromboplastin time; FIB, fibrinogen; AST, aspartate amino- transferase; ALT, alanine transaminase; ALB, albumin; GLB, globulin; ALP, alkaline phosphatase; GGT, gamma- glutamyl transferase; TBIL, total bilirubin; Cr, creatinine; AFP, alpha-fetoprotein; CTP, Child-Turcotte-Pugh stage; MELD, model for end-stage liver disease score; AASLD, American association for the study of liver disease; RFS, recurrence-free survival; ROC, receiver operating characteristic; AUROC, area under ROC curve; OR, odds ratio; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value; HR, hazard ratio. 1606 Journal of Hepatocellular Carcinoma 2023:10 https://doi.org/10.2147/JHC.S422632 DovePress Powered by TCPDF (www.tcpdf.org) Powered by TCPDF (www.tcpdf.org) Dovepress Chen et al Data Sharing Statement The datasets used and/or analyzed in this study are available from the corresponding authors on reasonable request. Ethics Approval and Informed Consent The studies involving human participants were reviewed and approved by the ethics committee of the Second Affiliated Hospital of Guangzhou University of Chinese Medicine (BE2022-226). The study was completed in accordance with the Declaration of Helsinki, and all patient data are treated confidentially. The requirement for written informed consent was waived by the Institutional Review Board in view of the retrospective observational nature of the research. Before Gd- EOB-DTPA enhanced MRI and curative hepatic resection, subjects received full information about indications, risks, and alternatives and then signed the written informed consent. Acknowledgments We thank Liwen Bianji (Edanz) for editing the English language in the draft of this manuscript. Author Contributions Conceptualization, Zhiyuan Chen, Xiaohuan Li, and Yupin Liu; design, Zhiyuan Chen, Dongjing Zhou, and Yupin Liu; Resources, Zhiyuan Chen, Yan Zhang, and Yupin Liu; execution, Xiaohuan Li, Yu Zhang, Yiming Yang, Yu Yang, and Shuping Zhang; acquisition of data, Xiaohuan Li, Yu Zhang, Yiming Yang, Yan Zhang, and Yu Yang; Formal Analysis, Zhiyuan Chen, Xiaohuan Li, Yan Zhang, and Dongjing Zhou;; Writing \u2013 Original Draft, Zhiyuan Chen, Xiaohuan Li, Yu Zhang, Yiming Yang, Yan Zhang, Yu Yang, and Shuping Zhang; Writing \u2013 Review & Editing, Zhiyuan Chen, Dongjing Zhou, and Yupin Liu. All authors made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; took part in drafting the article or revising it critically for important intellectual content; agreed to submit to the current journal; gave final approval of the version to be published; and agree to be accountable for all aspects of the work. Funding This work was funded by the Traditional Chinese medicine research project of the Second Affiliated Hospital of Guangzhou University of Chinese Medicine (YN2019QL09, ZY2022YL06). Disclosure The authors report no conflicts of interest in this work. References 1. Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400(10360):1345\u20131362. doi:10.1016/S0140- 6736(22)01200-4 2. Calderaro J, Seraphin TP, Luedde T, Simon TG. Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma. J Hepatol. 2022;76(6):1348\u20131361. 3. Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77(6):1598\u20131606. doi:10.1016/j.jhep.2022.08.021 4. Erstad DJ, Tanabe KK. Prognostic and therapeutic implications of microvascular invasion in hepatocellular carcinoma. Ann Surg Oncol. 2019;26 (5):1474\u20131493. doi:10.1245/s10434-019-07227-9 5. Beaufr\u00e8re A, Caruso S, Calderaro J, et al. Gene expression signature as a surrogate marker of microvascular invasion on routine hepatocellular carcinoma biopsies. J Hepatol. 2022;76(2):343\u2013352. doi:10.1016/j.jhep.2021.09.034 6. Wu Y, Zhu M, Liu Y, Cao X, Zhang G, Yin L. Peritumoral imaging manifestations on Gd-EOB-DTPA-enhanced MRI for preoperative prediction of microvascular invasion in hepatocellular carcinoma: a systematic review and meta-analysis. Front Oncol. 2022;12:907076. doi:10.3389/ fonc.2022.907076 7. Hong SB, Choi SH, Kim SY, et al. MRI features for predicting microvascular invasion of hepatocellular carcinoma: a systematic review and meta-analysis. Liver Cancer. 2021;10(2):94\u2013106. doi:10.1159/000513704 8. Rhee H, Cho ES, Nahm JH, et al. Gadoxetic acid-enhanced MRI of macrotrabecular-massive hepatocellular carcinoma and its prognostic implications. J Hepatol. 2021;74(1):109\u2013121. doi:10.1016/j.jhep.2020.08.013 9. Kang HJ, Kim H, Lee DH, et al. Gadoxetate-enhanced MRI features of proliferative hepatocellular carcinoma are prognostic after surgery. Radiology. 2021;300(3):572\u2013582. doi:10.1148/radiol.2021204352 10. Elsayes KM, Kielar AZ, Chernyak V, et al. LI-RADS: a conceptual and historical review from its beginning to its recent integration into AASLD clinical practice guidance. J Hepatocell Carcinoma. 2019;6:49\u201369. doi:10.2147/JHC.S186239 Journal of Hepatocellular Carcinoma 2023:10 https://doi.org/10.2147/JHC.S422632 1607 DovePress Powered by TCPDF (www.tcpdf.org) Powered by TCPDF (www.tcpdf.org) Chen et al Dovepress 11. Kim WR, Mannalithara A, Heimbach JK, et al. MELD 3.0: the model for end-stage liver disease updated for the modern era. Gastroenterology. 2021;161(6):1887\u20131895.e4. doi:10.1053/j.gastro.2021.08.050 12. Benchoufi M, Matzner-Lober E, Molinari N, Jannot AS, Soyer P. Interobserver agreement issues in radiology. Diagn Interv Imaging. 2020;101 (10):639\u2013641. doi:10.1016/j.diii.2020.09.001 13. He T, Zou J, Sun K, et al. Global research status and frontiers on microvascular invasion of hepatocellular carcinoma: a bibliometric and visualized analysis. Front Oncol. 2022;12:1037145. doi:10.3389/fonc.2022.1037145 14. Bai S, Yang P, Xie Z, et al. Preoperative estimated risk of microvascular invasion is associated with prognostic differences following liver resection versus radiofrequency ablation for early hepatitis b virus-related hepatocellular carcinoma. Ann Surg Oncol. 2021;28(13):8174\u20138185. doi:10.1245/ s10434-021-09901-3 15. Lee S, Kang TW, Song KD, et al. Effect of microvascular invasion risk on early recurrence of hepatocellular carcinoma after surgery and radiofrequency ablation. Ann Surg. 2021;273(3):564\u2013571. doi:10.1097/SLA.0000000000003268 16. Meng XP, Tang TY, Ding ZM, et al. preoperative microvascular invasion prediction to assist in surgical plan for single hepatocellular carcinoma: better together with radiomics. Ann Surg Oncol. 2022;29(5):2960\u20132970. doi:10.1245/s10434-022-11346-1 17. Zhang X, Li J, Shen F, Lau WY. Significance of presence of microvascular invasion in specimens obtained after surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol. 2018;33(2):347\u2013354. doi:10.1111/jgh.13843 18. Zhang L, Yu X, Wei W, et al. Prediction of HCC microvascular invasion with gadobenate-enhanced MRI: correlation with pathology. Eur Radiol. 2020;30(10):5327\u20135336. doi:10.1007/s00330-020-06895-6 19. Jiang H, Wei H, Yang T, et al. VICT2 trait: prognostic alternative to peritumoral hepatobiliary phase hypointensity in HCC. Radiology. 2023;307 (2):e221835. doi:10.1148/radiol.221835 20. Kitao A, Matsui O, Zhang Y,"}, {"question": " What is AFP in the text?", "answer": " AFP stands for alpha-fetoprotein.", "ref_chunk": "MVI, microvascular invasion; Gd-EOB-DTPA, gadolinium ethoxybenzyl diethylene- triamine pentaacetic acid; OATP, organic anion-transporting polypeptide; HBP, hepatobiliary phase; WBC, white blood cell count; RBC, red blood cell count; HB, hemoglobin; PLT, platelets; PT, prothrombin time; INR, international normalized ratio of prothrombin; APTT, activated partial thromboplastin time; FIB, fibrinogen; AST, aspartate amino- transferase; ALT, alanine transaminase; ALB, albumin; GLB, globulin; ALP, alkaline phosphatase; GGT, gamma- glutamyl transferase; TBIL, total bilirubin; Cr, creatinine; AFP, alpha-fetoprotein; CTP, Child-Turcotte-Pugh stage; MELD, model for end-stage liver disease score; AASLD, American association for the study of liver disease; RFS, recurrence-free survival; ROC, receiver operating characteristic; AUROC, area under ROC curve; OR, odds ratio; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value; HR, hazard ratio. 1606 Journal of Hepatocellular Carcinoma 2023:10 https://doi.org/10.2147/JHC.S422632 DovePress Powered by TCPDF (www.tcpdf.org) Powered by TCPDF (www.tcpdf.org) Dovepress Chen et al Data Sharing Statement The datasets used and/or analyzed in this study are available from the corresponding authors on reasonable request. Ethics Approval and Informed Consent The studies involving human participants were reviewed and approved by the ethics committee of the Second Affiliated Hospital of Guangzhou University of Chinese Medicine (BE2022-226). The study was completed in accordance with the Declaration of Helsinki, and all patient data are treated confidentially. The requirement for written informed consent was waived by the Institutional Review Board in view of the retrospective observational nature of the research. Before Gd- EOB-DTPA enhanced MRI and curative hepatic resection, subjects received full information about indications, risks, and alternatives and then signed the written informed consent. Acknowledgments We thank Liwen Bianji (Edanz) for editing the English language in the draft of this manuscript. Author Contributions Conceptualization, Zhiyuan Chen, Xiaohuan Li, and Yupin Liu; design, Zhiyuan Chen, Dongjing Zhou, and Yupin Liu; Resources, Zhiyuan Chen, Yan Zhang, and Yupin Liu; execution, Xiaohuan Li, Yu Zhang, Yiming Yang, Yu Yang, and Shuping Zhang; acquisition of data, Xiaohuan Li, Yu Zhang, Yiming Yang, Yan Zhang, and Yu Yang; Formal Analysis, Zhiyuan Chen, Xiaohuan Li, Yan Zhang, and Dongjing Zhou;; Writing \u2013 Original Draft, Zhiyuan Chen, Xiaohuan Li, Yu Zhang, Yiming Yang, Yan Zhang, Yu Yang, and Shuping Zhang; Writing \u2013 Review & Editing, Zhiyuan Chen, Dongjing Zhou, and Yupin Liu. All authors made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; took part in drafting the article or revising it critically for important intellectual content; agreed to submit to the current journal; gave final approval of the version to be published; and agree to be accountable for all aspects of the work. Funding This work was funded by the Traditional Chinese medicine research project of the Second Affiliated Hospital of Guangzhou University of Chinese Medicine (YN2019QL09, ZY2022YL06). Disclosure The authors report no conflicts of interest in this work. References 1. Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400(10360):1345\u20131362. doi:10.1016/S0140- 6736(22)01200-4 2. Calderaro J, Seraphin TP, Luedde T, Simon TG. Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma. J Hepatol. 2022;76(6):1348\u20131361. 3. Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77(6):1598\u20131606. doi:10.1016/j.jhep.2022.08.021 4. Erstad DJ, Tanabe KK. Prognostic and therapeutic implications of microvascular invasion in hepatocellular carcinoma. Ann Surg Oncol. 2019;26 (5):1474\u20131493. doi:10.1245/s10434-019-07227-9 5. Beaufr\u00e8re A, Caruso S, Calderaro J, et al. Gene expression signature as a surrogate marker of microvascular invasion on routine hepatocellular carcinoma biopsies. J Hepatol. 2022;76(2):343\u2013352. doi:10.1016/j.jhep.2021.09.034 6. Wu Y, Zhu M, Liu Y, Cao X, Zhang G, Yin L. Peritumoral imaging manifestations on Gd-EOB-DTPA-enhanced MRI for preoperative prediction of microvascular invasion in hepatocellular carcinoma: a systematic review and meta-analysis. Front Oncol. 2022;12:907076. doi:10.3389/ fonc.2022.907076 7. Hong SB, Choi SH, Kim SY, et al. MRI features for predicting microvascular invasion of hepatocellular carcinoma: a systematic review and meta-analysis. Liver Cancer. 2021;10(2):94\u2013106. doi:10.1159/000513704 8. Rhee H, Cho ES, Nahm JH, et al. Gadoxetic acid-enhanced MRI of macrotrabecular-massive hepatocellular carcinoma and its prognostic implications. J Hepatol. 2021;74(1):109\u2013121. doi:10.1016/j.jhep.2020.08.013 9. Kang HJ, Kim H, Lee DH, et al. Gadoxetate-enhanced MRI features of proliferative hepatocellular carcinoma are prognostic after surgery. Radiology. 2021;300(3):572\u2013582. doi:10.1148/radiol.2021204352 10. Elsayes KM, Kielar AZ, Chernyak V, et al. LI-RADS: a conceptual and historical review from its beginning to its recent integration into AASLD clinical practice guidance. J Hepatocell Carcinoma. 2019;6:49\u201369. doi:10.2147/JHC.S186239 Journal of Hepatocellular Carcinoma 2023:10 https://doi.org/10.2147/JHC.S422632 1607 DovePress Powered by TCPDF (www.tcpdf.org) Powered by TCPDF (www.tcpdf.org) Chen et al Dovepress 11. Kim WR, Mannalithara A, Heimbach JK, et al. MELD 3.0: the model for end-stage liver disease updated for the modern era. Gastroenterology. 2021;161(6):1887\u20131895.e4. doi:10.1053/j.gastro.2021.08.050 12. Benchoufi M, Matzner-Lober E, Molinari N, Jannot AS, Soyer P. Interobserver agreement issues in radiology. Diagn Interv Imaging. 2020;101 (10):639\u2013641. doi:10.1016/j.diii.2020.09.001 13. He T, Zou J, Sun K, et al. Global research status and frontiers on microvascular invasion of hepatocellular carcinoma: a bibliometric and visualized analysis. Front Oncol. 2022;12:1037145. doi:10.3389/fonc.2022.1037145 14. Bai S, Yang P, Xie Z, et al. Preoperative estimated risk of microvascular invasion is associated with prognostic differences following liver resection versus radiofrequency ablation for early hepatitis b virus-related hepatocellular carcinoma. Ann Surg Oncol. 2021;28(13):8174\u20138185. doi:10.1245/ s10434-021-09901-3 15. Lee S, Kang TW, Song KD, et al. Effect of microvascular invasion risk on early recurrence of hepatocellular carcinoma after surgery and radiofrequency ablation. Ann Surg. 2021;273(3):564\u2013571. doi:10.1097/SLA.0000000000003268 16. Meng XP, Tang TY, Ding ZM, et al. preoperative microvascular invasion prediction to assist in surgical plan for single hepatocellular carcinoma: better together with radiomics. Ann Surg Oncol. 2022;29(5):2960\u20132970. doi:10.1245/s10434-022-11346-1 17. Zhang X, Li J, Shen F, Lau WY. Significance of presence of microvascular invasion in specimens obtained after surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol. 2018;33(2):347\u2013354. doi:10.1111/jgh.13843 18. Zhang L, Yu X, Wei W, et al. Prediction of HCC microvascular invasion with gadobenate-enhanced MRI: correlation with pathology. Eur Radiol. 2020;30(10):5327\u20135336. doi:10.1007/s00330-020-06895-6 19. Jiang H, Wei H, Yang T, et al. VICT2 trait: prognostic alternative to peritumoral hepatobiliary phase hypointensity in HCC. Radiology. 2023;307 (2):e221835. doi:10.1148/radiol.221835 20. Kitao A, Matsui O, Zhang Y,"}, {"question": " What organization funded the work mentioned?", "answer": " The work was funded by the Traditional Chinese medicine research project of the Second Affiliated Hospital of Guangzhou University of Chinese Medicine.", "ref_chunk": "MVI, microvascular invasion; Gd-EOB-DTPA, gadolinium ethoxybenzyl diethylene- triamine pentaacetic acid; OATP, organic anion-transporting polypeptide; HBP, hepatobiliary phase; WBC, white blood cell count; RBC, red blood cell count; HB, hemoglobin; PLT, platelets; PT, prothrombin time; INR, international normalized ratio of prothrombin; APTT, activated partial thromboplastin time; FIB, fibrinogen; AST, aspartate amino- transferase; ALT, alanine transaminase; ALB, albumin; GLB, globulin; ALP, alkaline phosphatase; GGT, gamma- glutamyl transferase; TBIL, total bilirubin; Cr, creatinine; AFP, alpha-fetoprotein; CTP, Child-Turcotte-Pugh stage; MELD, model for end-stage liver disease score; AASLD, American association for the study of liver disease; RFS, recurrence-free survival; ROC, receiver operating characteristic; AUROC, area under ROC curve; OR, odds ratio; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value; HR, hazard ratio. 1606 Journal of Hepatocellular Carcinoma 2023:10 https://doi.org/10.2147/JHC.S422632 DovePress Powered by TCPDF (www.tcpdf.org) Powered by TCPDF (www.tcpdf.org) Dovepress Chen et al Data Sharing Statement The datasets used and/or analyzed in this study are available from the corresponding authors on reasonable request. Ethics Approval and Informed Consent The studies involving human participants were reviewed and approved by the ethics committee of the Second Affiliated Hospital of Guangzhou University of Chinese Medicine (BE2022-226). The study was completed in accordance with the Declaration of Helsinki, and all patient data are treated confidentially. The requirement for written informed consent was waived by the Institutional Review Board in view of the retrospective observational nature of the research. Before Gd- EOB-DTPA enhanced MRI and curative hepatic resection, subjects received full information about indications, risks, and alternatives and then signed the written informed consent. Acknowledgments We thank Liwen Bianji (Edanz) for editing the English language in the draft of this manuscript. Author Contributions Conceptualization, Zhiyuan Chen, Xiaohuan Li, and Yupin Liu; design, Zhiyuan Chen, Dongjing Zhou, and Yupin Liu; Resources, Zhiyuan Chen, Yan Zhang, and Yupin Liu; execution, Xiaohuan Li, Yu Zhang, Yiming Yang, Yu Yang, and Shuping Zhang; acquisition of data, Xiaohuan Li, Yu Zhang, Yiming Yang, Yan Zhang, and Yu Yang; Formal Analysis, Zhiyuan Chen, Xiaohuan Li, Yan Zhang, and Dongjing Zhou;; Writing \u2013 Original Draft, Zhiyuan Chen, Xiaohuan Li, Yu Zhang, Yiming Yang, Yan Zhang, Yu Yang, and Shuping Zhang; Writing \u2013 Review & Editing, Zhiyuan Chen, Dongjing Zhou, and Yupin Liu. All authors made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; took part in drafting the article or revising it critically for important intellectual content; agreed to submit to the current journal; gave final approval of the version to be published; and agree to be accountable for all aspects of the work. Funding This work was funded by the Traditional Chinese medicine research project of the Second Affiliated Hospital of Guangzhou University of Chinese Medicine (YN2019QL09, ZY2022YL06). Disclosure The authors report no conflicts of interest in this work. References 1. Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400(10360):1345\u20131362. doi:10.1016/S0140- 6736(22)01200-4 2. Calderaro J, Seraphin TP, Luedde T, Simon TG. Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma. J Hepatol. 2022;76(6):1348\u20131361. 3. Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77(6):1598\u20131606. doi:10.1016/j.jhep.2022.08.021 4. Erstad DJ, Tanabe KK. Prognostic and therapeutic implications of microvascular invasion in hepatocellular carcinoma. Ann Surg Oncol. 2019;26 (5):1474\u20131493. doi:10.1245/s10434-019-07227-9 5. Beaufr\u00e8re A, Caruso S, Calderaro J, et al. Gene expression signature as a surrogate marker of microvascular invasion on routine hepatocellular carcinoma biopsies. J Hepatol. 2022;76(2):343\u2013352. doi:10.1016/j.jhep.2021.09.034 6. Wu Y, Zhu M, Liu Y, Cao X, Zhang G, Yin L. Peritumoral imaging manifestations on Gd-EOB-DTPA-enhanced MRI for preoperative prediction of microvascular invasion in hepatocellular carcinoma: a systematic review and meta-analysis. Front Oncol. 2022;12:907076. doi:10.3389/ fonc.2022.907076 7. Hong SB, Choi SH, Kim SY, et al. MRI features for predicting microvascular invasion of hepatocellular carcinoma: a systematic review and meta-analysis. Liver Cancer. 2021;10(2):94\u2013106. doi:10.1159/000513704 8. Rhee H, Cho ES, Nahm JH, et al. Gadoxetic acid-enhanced MRI of macrotrabecular-massive hepatocellular carcinoma and its prognostic implications. J Hepatol. 2021;74(1):109\u2013121. doi:10.1016/j.jhep.2020.08.013 9. Kang HJ, Kim H, Lee DH, et al. Gadoxetate-enhanced MRI features of proliferative hepatocellular carcinoma are prognostic after surgery. Radiology. 2021;300(3):572\u2013582. doi:10.1148/radiol.2021204352 10. Elsayes KM, Kielar AZ, Chernyak V, et al. LI-RADS: a conceptual and historical review from its beginning to its recent integration into AASLD clinical practice guidance. J Hepatocell Carcinoma. 2019;6:49\u201369. doi:10.2147/JHC.S186239 Journal of Hepatocellular Carcinoma 2023:10 https://doi.org/10.2147/JHC.S422632 1607 DovePress Powered by TCPDF (www.tcpdf.org) Powered by TCPDF (www.tcpdf.org) Chen et al Dovepress 11. Kim WR, Mannalithara A, Heimbach JK, et al. MELD 3.0: the model for end-stage liver disease updated for the modern era. Gastroenterology. 2021;161(6):1887\u20131895.e4. doi:10.1053/j.gastro.2021.08.050 12. Benchoufi M, Matzner-Lober E, Molinari N, Jannot AS, Soyer P. Interobserver agreement issues in radiology. Diagn Interv Imaging. 2020;101 (10):639\u2013641. doi:10.1016/j.diii.2020.09.001 13. He T, Zou J, Sun K, et al. Global research status and frontiers on microvascular invasion of hepatocellular carcinoma: a bibliometric and visualized analysis. Front Oncol. 2022;12:1037145. doi:10.3389/fonc.2022.1037145 14. Bai S, Yang P, Xie Z, et al. Preoperative estimated risk of microvascular invasion is associated with prognostic differences following liver resection versus radiofrequency ablation for early hepatitis b virus-related hepatocellular carcinoma. Ann Surg Oncol. 2021;28(13):8174\u20138185. doi:10.1245/ s10434-021-09901-3 15. Lee S, Kang TW, Song KD, et al. Effect of microvascular invasion risk on early recurrence of hepatocellular carcinoma after surgery and radiofrequency ablation. Ann Surg. 2021;273(3):564\u2013571. doi:10.1097/SLA.0000000000003268 16. Meng XP, Tang TY, Ding ZM, et al. preoperative microvascular invasion prediction to assist in surgical plan for single hepatocellular carcinoma: better together with radiomics. Ann Surg Oncol. 2022;29(5):2960\u20132970. doi:10.1245/s10434-022-11346-1 17. Zhang X, Li J, Shen F, Lau WY. Significance of presence of microvascular invasion in specimens obtained after surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol. 2018;33(2):347\u2013354. doi:10.1111/jgh.13843 18. Zhang L, Yu X, Wei W, et al. Prediction of HCC microvascular invasion with gadobenate-enhanced MRI: correlation with pathology. Eur Radiol. 2020;30(10):5327\u20135336. doi:10.1007/s00330-020-06895-6 19. Jiang H, Wei H, Yang T, et al. VICT2 trait: prognostic alternative to peritumoral hepatobiliary phase hypointensity in HCC. Radiology. 2023;307 (2):e221835. doi:10.1148/radiol.221835 20. Kitao A, Matsui O, Zhang Y,"}, {"question": " What does ROC stand for in the text?", "answer": " ROC stands for receiver operating characteristic.", "ref_chunk": "MVI, microvascular invasion; Gd-EOB-DTPA, gadolinium ethoxybenzyl diethylene- triamine pentaacetic acid; OATP, organic anion-transporting polypeptide; HBP, hepatobiliary phase; WBC, white blood cell count; RBC, red blood cell count; HB, hemoglobin; PLT, platelets; PT, prothrombin time; INR, international normalized ratio of prothrombin; APTT, activated partial thromboplastin time; FIB, fibrinogen; AST, aspartate amino- transferase; ALT, alanine transaminase; ALB, albumin; GLB, globulin; ALP, alkaline phosphatase; GGT, gamma- glutamyl transferase; TBIL, total bilirubin; Cr, creatinine; AFP, alpha-fetoprotein; CTP, Child-Turcotte-Pugh stage; MELD, model for end-stage liver disease score; AASLD, American association for the study of liver disease; RFS, recurrence-free survival; ROC, receiver operating characteristic; AUROC, area under ROC curve; OR, odds ratio; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value; HR, hazard ratio. 1606 Journal of Hepatocellular Carcinoma 2023:10 https://doi.org/10.2147/JHC.S422632 DovePress Powered by TCPDF (www.tcpdf.org) Powered by TCPDF (www.tcpdf.org) Dovepress Chen et al Data Sharing Statement The datasets used and/or analyzed in this study are available from the corresponding authors on reasonable request. Ethics Approval and Informed Consent The studies involving human participants were reviewed and approved by the ethics committee of the Second Affiliated Hospital of Guangzhou University of Chinese Medicine (BE2022-226). The study was completed in accordance with the Declaration of Helsinki, and all patient data are treated confidentially. The requirement for written informed consent was waived by the Institutional Review Board in view of the retrospective observational nature of the research. Before Gd- EOB-DTPA enhanced MRI and curative hepatic resection, subjects received full information about indications, risks, and alternatives and then signed the written informed consent. Acknowledgments We thank Liwen Bianji (Edanz) for editing the English language in the draft of this manuscript. Author Contributions Conceptualization, Zhiyuan Chen, Xiaohuan Li, and Yupin Liu; design, Zhiyuan Chen, Dongjing Zhou, and Yupin Liu; Resources, Zhiyuan Chen, Yan Zhang, and Yupin Liu; execution, Xiaohuan Li, Yu Zhang, Yiming Yang, Yu Yang, and Shuping Zhang; acquisition of data, Xiaohuan Li, Yu Zhang, Yiming Yang, Yan Zhang, and Yu Yang; Formal Analysis, Zhiyuan Chen, Xiaohuan Li, Yan Zhang, and Dongjing Zhou;; Writing \u2013 Original Draft, Zhiyuan Chen, Xiaohuan Li, Yu Zhang, Yiming Yang, Yan Zhang, Yu Yang, and Shuping Zhang; Writing \u2013 Review & Editing, Zhiyuan Chen, Dongjing Zhou, and Yupin Liu. All authors made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; took part in drafting the article or revising it critically for important intellectual content; agreed to submit to the current journal; gave final approval of the version to be published; and agree to be accountable for all aspects of the work. Funding This work was funded by the Traditional Chinese medicine research project of the Second Affiliated Hospital of Guangzhou University of Chinese Medicine (YN2019QL09, ZY2022YL06). Disclosure The authors report no conflicts of interest in this work. References 1. Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400(10360):1345\u20131362. doi:10.1016/S0140- 6736(22)01200-4 2. Calderaro J, Seraphin TP, Luedde T, Simon TG. Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma. J Hepatol. 2022;76(6):1348\u20131361. 3. Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77(6):1598\u20131606. doi:10.1016/j.jhep.2022.08.021 4. Erstad DJ, Tanabe KK. Prognostic and therapeutic implications of microvascular invasion in hepatocellular carcinoma. Ann Surg Oncol. 2019;26 (5):1474\u20131493. doi:10.1245/s10434-019-07227-9 5. Beaufr\u00e8re A, Caruso S, Calderaro J, et al. Gene expression signature as a surrogate marker of microvascular invasion on routine hepatocellular carcinoma biopsies. J Hepatol. 2022;76(2):343\u2013352. doi:10.1016/j.jhep.2021.09.034 6. Wu Y, Zhu M, Liu Y, Cao X, Zhang G, Yin L. Peritumoral imaging manifestations on Gd-EOB-DTPA-enhanced MRI for preoperative prediction of microvascular invasion in hepatocellular carcinoma: a systematic review and meta-analysis. Front Oncol. 2022;12:907076. doi:10.3389/ fonc.2022.907076 7. Hong SB, Choi SH, Kim SY, et al. MRI features for predicting microvascular invasion of hepatocellular carcinoma: a systematic review and meta-analysis. Liver Cancer. 2021;10(2):94\u2013106. doi:10.1159/000513704 8. Rhee H, Cho ES, Nahm JH, et al. Gadoxetic acid-enhanced MRI of macrotrabecular-massive hepatocellular carcinoma and its prognostic implications. J Hepatol. 2021;74(1):109\u2013121. doi:10.1016/j.jhep.2020.08.013 9. Kang HJ, Kim H, Lee DH, et al. Gadoxetate-enhanced MRI features of proliferative hepatocellular carcinoma are prognostic after surgery. Radiology. 2021;300(3):572\u2013582. doi:10.1148/radiol.2021204352 10. Elsayes KM, Kielar AZ, Chernyak V, et al. LI-RADS: a conceptual and historical review from its beginning to its recent integration into AASLD clinical practice guidance. J Hepatocell Carcinoma. 2019;6:49\u201369. doi:10.2147/JHC.S186239 Journal of Hepatocellular Carcinoma 2023:10 https://doi.org/10.2147/JHC.S422632 1607 DovePress Powered by TCPDF (www.tcpdf.org) Powered by TCPDF (www.tcpdf.org) Chen et al Dovepress 11. Kim WR, Mannalithara A, Heimbach JK, et al. MELD 3.0: the model for end-stage liver disease updated for the modern era. Gastroenterology. 2021;161(6):1887\u20131895.e4. doi:10.1053/j.gastro.2021.08.050 12. Benchoufi M, Matzner-Lober E, Molinari N, Jannot AS, Soyer P. Interobserver agreement issues in radiology. Diagn Interv Imaging. 2020;101 (10):639\u2013641. doi:10.1016/j.diii.2020.09.001 13. He T, Zou J, Sun K, et al. Global research status and frontiers on microvascular invasion of hepatocellular carcinoma: a bibliometric and visualized analysis. Front Oncol. 2022;12:1037145. doi:10.3389/fonc.2022.1037145 14. Bai S, Yang P, Xie Z, et al. Preoperative estimated risk of microvascular invasion is associated with prognostic differences following liver resection versus radiofrequency ablation for early hepatitis b virus-related hepatocellular carcinoma. Ann Surg Oncol. 2021;28(13):8174\u20138185. doi:10.1245/ s10434-021-09901-3 15. Lee S, Kang TW, Song KD, et al. Effect of microvascular invasion risk on early recurrence of hepatocellular carcinoma after surgery and radiofrequency ablation. Ann Surg. 2021;273(3):564\u2013571. doi:10.1097/SLA.0000000000003268 16. Meng XP, Tang TY, Ding ZM, et al. preoperative microvascular invasion prediction to assist in surgical plan for single hepatocellular carcinoma: better together with radiomics. Ann Surg Oncol. 2022;29(5):2960\u20132970. doi:10.1245/s10434-022-11346-1 17. Zhang X, Li J, Shen F, Lau WY. Significance of presence of microvascular invasion in specimens obtained after surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol. 2018;33(2):347\u2013354. doi:10.1111/jgh.13843 18. Zhang L, Yu X, Wei W, et al. Prediction of HCC microvascular invasion with gadobenate-enhanced MRI: correlation with pathology. Eur Radiol. 2020;30(10):5327\u20135336. doi:10.1007/s00330-020-06895-6 19. Jiang H, Wei H, Yang T, et al. VICT2 trait: prognostic alternative to peritumoral hepatobiliary phase hypointensity in HCC. Radiology. 2023;307 (2):e221835. doi:10.1148/radiol.221835 20. Kitao A, Matsui O, Zhang Y,"}, {"question": " What is the purpose of AUROC in the context of the text?", "answer": " AUROC stands for area under ROC curve and is used for prediction and classification.", "ref_chunk": "MVI, microvascular invasion; Gd-EOB-DTPA, gadolinium ethoxybenzyl diethylene- triamine pentaacetic acid; OATP, organic anion-transporting polypeptide; HBP, hepatobiliary phase; WBC, white blood cell count; RBC, red blood cell count; HB, hemoglobin; PLT, platelets; PT, prothrombin time; INR, international normalized ratio of prothrombin; APTT, activated partial thromboplastin time; FIB, fibrinogen; AST, aspartate amino- transferase; ALT, alanine transaminase; ALB, albumin; GLB, globulin; ALP, alkaline phosphatase; GGT, gamma- glutamyl transferase; TBIL, total bilirubin; Cr, creatinine; AFP, alpha-fetoprotein; CTP, Child-Turcotte-Pugh stage; MELD, model for end-stage liver disease score; AASLD, American association for the study of liver disease; RFS, recurrence-free survival; ROC, receiver operating characteristic; AUROC, area under ROC curve; OR, odds ratio; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value; HR, hazard ratio. 1606 Journal of Hepatocellular Carcinoma 2023:10 https://doi.org/10.2147/JHC.S422632 DovePress Powered by TCPDF (www.tcpdf.org) Powered by TCPDF (www.tcpdf.org) Dovepress Chen et al Data Sharing Statement The datasets used and/or analyzed in this study are available from the corresponding authors on reasonable request. Ethics Approval and Informed Consent The studies involving human participants were reviewed and approved by the ethics committee of the Second Affiliated Hospital of Guangzhou University of Chinese Medicine (BE2022-226). The study was completed in accordance with the Declaration of Helsinki, and all patient data are treated confidentially. The requirement for written informed consent was waived by the Institutional Review Board in view of the retrospective observational nature of the research. Before Gd- EOB-DTPA enhanced MRI and curative hepatic resection, subjects received full information about indications, risks, and alternatives and then signed the written informed consent. Acknowledgments We thank Liwen Bianji (Edanz) for editing the English language in the draft of this manuscript. Author Contributions Conceptualization, Zhiyuan Chen, Xiaohuan Li, and Yupin Liu; design, Zhiyuan Chen, Dongjing Zhou, and Yupin Liu; Resources, Zhiyuan Chen, Yan Zhang, and Yupin Liu; execution, Xiaohuan Li, Yu Zhang, Yiming Yang, Yu Yang, and Shuping Zhang; acquisition of data, Xiaohuan Li, Yu Zhang, Yiming Yang, Yan Zhang, and Yu Yang; Formal Analysis, Zhiyuan Chen, Xiaohuan Li, Yan Zhang, and Dongjing Zhou;; Writing \u2013 Original Draft, Zhiyuan Chen, Xiaohuan Li, Yu Zhang, Yiming Yang, Yan Zhang, Yu Yang, and Shuping Zhang; Writing \u2013 Review & Editing, Zhiyuan Chen, Dongjing Zhou, and Yupin Liu. All authors made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; took part in drafting the article or revising it critically for important intellectual content; agreed to submit to the current journal; gave final approval of the version to be published; and agree to be accountable for all aspects of the work. Funding This work was funded by the Traditional Chinese medicine research project of the Second Affiliated Hospital of Guangzhou University of Chinese Medicine (YN2019QL09, ZY2022YL06). Disclosure The authors report no conflicts of interest in this work. References 1. Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400(10360):1345\u20131362. doi:10.1016/S0140- 6736(22)01200-4 2. Calderaro J, Seraphin TP, Luedde T, Simon TG. Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma. J Hepatol. 2022;76(6):1348\u20131361. 3. Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77(6):1598\u20131606. doi:10.1016/j.jhep.2022.08.021 4. Erstad DJ, Tanabe KK. Prognostic and therapeutic implications of microvascular invasion in hepatocellular carcinoma. Ann Surg Oncol. 2019;26 (5):1474\u20131493. doi:10.1245/s10434-019-07227-9 5. Beaufr\u00e8re A, Caruso S, Calderaro J, et al. Gene expression signature as a surrogate marker of microvascular invasion on routine hepatocellular carcinoma biopsies. J Hepatol. 2022;76(2):343\u2013352. doi:10.1016/j.jhep.2021.09.034 6. Wu Y, Zhu M, Liu Y, Cao X, Zhang G, Yin L. Peritumoral imaging manifestations on Gd-EOB-DTPA-enhanced MRI for preoperative prediction of microvascular invasion in hepatocellular carcinoma: a systematic review and meta-analysis. Front Oncol. 2022;12:907076. doi:10.3389/ fonc.2022.907076 7. Hong SB, Choi SH, Kim SY, et al. MRI features for predicting microvascular invasion of hepatocellular carcinoma: a systematic review and meta-analysis. Liver Cancer. 2021;10(2):94\u2013106. doi:10.1159/000513704 8. Rhee H, Cho ES, Nahm JH, et al. Gadoxetic acid-enhanced MRI of macrotrabecular-massive hepatocellular carcinoma and its prognostic implications. J Hepatol. 2021;74(1):109\u2013121. doi:10.1016/j.jhep.2020.08.013 9. Kang HJ, Kim H, Lee DH, et al. Gadoxetate-enhanced MRI features of proliferative hepatocellular carcinoma are prognostic after surgery. Radiology. 2021;300(3):572\u2013582. doi:10.1148/radiol.2021204352 10. Elsayes KM, Kielar AZ, Chernyak V, et al. LI-RADS: a conceptual and historical review from its beginning to its recent integration into AASLD clinical practice guidance. J Hepatocell Carcinoma. 2019;6:49\u201369. doi:10.2147/JHC.S186239 Journal of Hepatocellular Carcinoma 2023:10 https://doi.org/10.2147/JHC.S422632 1607 DovePress Powered by TCPDF (www.tcpdf.org) Powered by TCPDF (www.tcpdf.org) Chen et al Dovepress 11. Kim WR, Mannalithara A, Heimbach JK, et al. MELD 3.0: the model for end-stage liver disease updated for the modern era. Gastroenterology. 2021;161(6):1887\u20131895.e4. doi:10.1053/j.gastro.2021.08.050 12. Benchoufi M, Matzner-Lober E, Molinari N, Jannot AS, Soyer P. Interobserver agreement issues in radiology. Diagn Interv Imaging. 2020;101 (10):639\u2013641. doi:10.1016/j.diii.2020.09.001 13. He T, Zou J, Sun K, et al. Global research status and frontiers on microvascular invasion of hepatocellular carcinoma: a bibliometric and visualized analysis. Front Oncol. 2022;12:1037145. doi:10.3389/fonc.2022.1037145 14. Bai S, Yang P, Xie Z, et al. Preoperative estimated risk of microvascular invasion is associated with prognostic differences following liver resection versus radiofrequency ablation for early hepatitis b virus-related hepatocellular carcinoma. Ann Surg Oncol. 2021;28(13):8174\u20138185. doi:10.1245/ s10434-021-09901-3 15. Lee S, Kang TW, Song KD, et al. Effect of microvascular invasion risk on early recurrence of hepatocellular carcinoma after surgery and radiofrequency ablation. Ann Surg. 2021;273(3):564\u2013571. doi:10.1097/SLA.0000000000003268 16. Meng XP, Tang TY, Ding ZM, et al. preoperative microvascular invasion prediction to assist in surgical plan for single hepatocellular carcinoma: better together with radiomics. Ann Surg Oncol. 2022;29(5):2960\u20132970. doi:10.1245/s10434-022-11346-1 17. Zhang X, Li J, Shen F, Lau WY. Significance of presence of microvascular invasion in specimens obtained after surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol. 2018;33(2):347\u2013354. doi:10.1111/jgh.13843 18. Zhang L, Yu X, Wei W, et al. Prediction of HCC microvascular invasion with gadobenate-enhanced MRI: correlation with pathology. Eur Radiol. 2020;30(10):5327\u20135336. doi:10.1007/s00330-020-06895-6 19. Jiang H, Wei H, Yang T, et al. VICT2 trait: prognostic alternative to peritumoral hepatobiliary phase hypointensity in HCC. Radiology. 2023;307 (2):e221835. doi:10.1148/radiol.221835 20. Kitao A, Matsui O, Zhang Y,"}, {"question": " What does PPV represent in the text?", "answer": " PPV stands for positive predictive value.", "ref_chunk": "MVI, microvascular invasion; Gd-EOB-DTPA, gadolinium ethoxybenzyl diethylene- triamine pentaacetic acid; OATP, organic anion-transporting polypeptide; HBP, hepatobiliary phase; WBC, white blood cell count; RBC, red blood cell count; HB, hemoglobin; PLT, platelets; PT, prothrombin time; INR, international normalized ratio of prothrombin; APTT, activated partial thromboplastin time; FIB, fibrinogen; AST, aspartate amino- transferase; ALT, alanine transaminase; ALB, albumin; GLB, globulin; ALP, alkaline phosphatase; GGT, gamma- glutamyl transferase; TBIL, total bilirubin; Cr, creatinine; AFP, alpha-fetoprotein; CTP, Child-Turcotte-Pugh stage; MELD, model for end-stage liver disease score; AASLD, American association for the study of liver disease; RFS, recurrence-free survival; ROC, receiver operating characteristic; AUROC, area under ROC curve; OR, odds ratio; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value; HR, hazard ratio. 1606 Journal of Hepatocellular Carcinoma 2023:10 https://doi.org/10.2147/JHC.S422632 DovePress Powered by TCPDF (www.tcpdf.org) Powered by TCPDF (www.tcpdf.org) Dovepress Chen et al Data Sharing Statement The datasets used and/or analyzed in this study are available from the corresponding authors on reasonable request. Ethics Approval and Informed Consent The studies involving human participants were reviewed and approved by the ethics committee of the Second Affiliated Hospital of Guangzhou University of Chinese Medicine (BE2022-226). The study was completed in accordance with the Declaration of Helsinki, and all patient data are treated confidentially. The requirement for written informed consent was waived by the Institutional Review Board in view of the retrospective observational nature of the research. Before Gd- EOB-DTPA enhanced MRI and curative hepatic resection, subjects received full information about indications, risks, and alternatives and then signed the written informed consent. Acknowledgments We thank Liwen Bianji (Edanz) for editing the English language in the draft of this manuscript. Author Contributions Conceptualization, Zhiyuan Chen, Xiaohuan Li, and Yupin Liu; design, Zhiyuan Chen, Dongjing Zhou, and Yupin Liu; Resources, Zhiyuan Chen, Yan Zhang, and Yupin Liu; execution, Xiaohuan Li, Yu Zhang, Yiming Yang, Yu Yang, and Shuping Zhang; acquisition of data, Xiaohuan Li, Yu Zhang, Yiming Yang, Yan Zhang, and Yu Yang; Formal Analysis, Zhiyuan Chen, Xiaohuan Li, Yan Zhang, and Dongjing Zhou;; Writing \u2013 Original Draft, Zhiyuan Chen, Xiaohuan Li, Yu Zhang, Yiming Yang, Yan Zhang, Yu Yang, and Shuping Zhang; Writing \u2013 Review & Editing, Zhiyuan Chen, Dongjing Zhou, and Yupin Liu. All authors made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; took part in drafting the article or revising it critically for important intellectual content; agreed to submit to the current journal; gave final approval of the version to be published; and agree to be accountable for all aspects of the work. Funding This work was funded by the Traditional Chinese medicine research project of the Second Affiliated Hospital of Guangzhou University of Chinese Medicine (YN2019QL09, ZY2022YL06). Disclosure The authors report no conflicts of interest in this work. References 1. Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400(10360):1345\u20131362. doi:10.1016/S0140- 6736(22)01200-4 2. Calderaro J, Seraphin TP, Luedde T, Simon TG. Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma. J Hepatol. 2022;76(6):1348\u20131361. 3. Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77(6):1598\u20131606. doi:10.1016/j.jhep.2022.08.021 4. Erstad DJ, Tanabe KK. Prognostic and therapeutic implications of microvascular invasion in hepatocellular carcinoma. Ann Surg Oncol. 2019;26 (5):1474\u20131493. doi:10.1245/s10434-019-07227-9 5. Beaufr\u00e8re A, Caruso S, Calderaro J, et al. Gene expression signature as a surrogate marker of microvascular invasion on routine hepatocellular carcinoma biopsies. J Hepatol. 2022;76(2):343\u2013352. doi:10.1016/j.jhep.2021.09.034 6. Wu Y, Zhu M, Liu Y, Cao X, Zhang G, Yin L. Peritumoral imaging manifestations on Gd-EOB-DTPA-enhanced MRI for preoperative prediction of microvascular invasion in hepatocellular carcinoma: a systematic review and meta-analysis. Front Oncol. 2022;12:907076. doi:10.3389/ fonc.2022.907076 7. Hong SB, Choi SH, Kim SY, et al. MRI features for predicting microvascular invasion of hepatocellular carcinoma: a systematic review and meta-analysis. Liver Cancer. 2021;10(2):94\u2013106. doi:10.1159/000513704 8. Rhee H, Cho ES, Nahm JH, et al. Gadoxetic acid-enhanced MRI of macrotrabecular-massive hepatocellular carcinoma and its prognostic implications. J Hepatol. 2021;74(1):109\u2013121. doi:10.1016/j.jhep.2020.08.013 9. Kang HJ, Kim H, Lee DH, et al. Gadoxetate-enhanced MRI features of proliferative hepatocellular carcinoma are prognostic after surgery. Radiology. 2021;300(3):572\u2013582. doi:10.1148/radiol.2021204352 10. Elsayes KM, Kielar AZ, Chernyak V, et al. LI-RADS: a conceptual and historical review from its beginning to its recent integration into AASLD clinical practice guidance. J Hepatocell Carcinoma. 2019;6:49\u201369. doi:10.2147/JHC.S186239 Journal of Hepatocellular Carcinoma 2023:10 https://doi.org/10.2147/JHC.S422632 1607 DovePress Powered by TCPDF (www.tcpdf.org) Powered by TCPDF (www.tcpdf.org) Chen et al Dovepress 11. Kim WR, Mannalithara A, Heimbach JK, et al. MELD 3.0: the model for end-stage liver disease updated for the modern era. Gastroenterology. 2021;161(6):1887\u20131895.e4. doi:10.1053/j.gastro.2021.08.050 12. Benchoufi M, Matzner-Lober E, Molinari N, Jannot AS, Soyer P. Interobserver agreement issues in radiology. Diagn Interv Imaging. 2020;101 (10):639\u2013641. doi:10.1016/j.diii.2020.09.001 13. He T, Zou J, Sun K, et al. Global research status and frontiers on microvascular invasion of hepatocellular carcinoma: a bibliometric and visualized analysis. Front Oncol. 2022;12:1037145. doi:10.3389/fonc.2022.1037145 14. Bai S, Yang P, Xie Z, et al. Preoperative estimated risk of microvascular invasion is associated with prognostic differences following liver resection versus radiofrequency ablation for early hepatitis b virus-related hepatocellular carcinoma. Ann Surg Oncol. 2021;28(13):8174\u20138185. doi:10.1245/ s10434-021-09901-3 15. Lee S, Kang TW, Song KD, et al. Effect of microvascular invasion risk on early recurrence of hepatocellular carcinoma after surgery and radiofrequency ablation. Ann Surg. 2021;273(3):564\u2013571. doi:10.1097/SLA.0000000000003268 16. Meng XP, Tang TY, Ding ZM, et al. preoperative microvascular invasion prediction to assist in surgical plan for single hepatocellular carcinoma: better together with radiomics. Ann Surg Oncol. 2022;29(5):2960\u20132970. doi:10.1245/s10434-022-11346-1 17. Zhang X, Li J, Shen F, Lau WY. Significance of presence of microvascular invasion in specimens obtained after surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol. 2018;33(2):347\u2013354. doi:10.1111/jgh.13843 18. Zhang L, Yu X, Wei W, et al. Prediction of HCC microvascular invasion with gadobenate-enhanced MRI: correlation with pathology. Eur Radiol. 2020;30(10):5327\u20135336. doi:10.1007/s00330-020-06895-6 19. Jiang H, Wei H, Yang T, et al. VICT2 trait: prognostic alternative to peritumoral hepatobiliary phase hypointensity in HCC. Radiology. 2023;307 (2):e221835. doi:10.1148/radiol.221835 20. Kitao A, Matsui O, Zhang Y,"}, {"question": " What is the significance of the VICT2 trait mentioned in the text?", "answer": " The VICT2 trait is a prognostic alternative to peritumoral hepatobiliary phase hypointensity in HCC.", "ref_chunk": "MVI, microvascular invasion; Gd-EOB-DTPA, gadolinium ethoxybenzyl diethylene- triamine pentaacetic acid; OATP, organic anion-transporting polypeptide; HBP, hepatobiliary phase; WBC, white blood cell count; RBC, red blood cell count; HB, hemoglobin; PLT, platelets; PT, prothrombin time; INR, international normalized ratio of prothrombin; APTT, activated partial thromboplastin time; FIB, fibrinogen; AST, aspartate amino- transferase; ALT, alanine transaminase; ALB, albumin; GLB, globulin; ALP, alkaline phosphatase; GGT, gamma- glutamyl transferase; TBIL, total bilirubin; Cr, creatinine; AFP, alpha-fetoprotein; CTP, Child-Turcotte-Pugh stage; MELD, model for end-stage liver disease score; AASLD, American association for the study of liver disease; RFS, recurrence-free survival; ROC, receiver operating characteristic; AUROC, area under ROC curve; OR, odds ratio; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value; HR, hazard ratio. 1606 Journal of Hepatocellular Carcinoma 2023:10 https://doi.org/10.2147/JHC.S422632 DovePress Powered by TCPDF (www.tcpdf.org) Powered by TCPDF (www.tcpdf.org) Dovepress Chen et al Data Sharing Statement The datasets used and/or analyzed in this study are available from the corresponding authors on reasonable request. Ethics Approval and Informed Consent The studies involving human participants were reviewed and approved by the ethics committee of the Second Affiliated Hospital of Guangzhou University of Chinese Medicine (BE2022-226). The study was completed in accordance with the Declaration of Helsinki, and all patient data are treated confidentially. The requirement for written informed consent was waived by the Institutional Review Board in view of the retrospective observational nature of the research. Before Gd- EOB-DTPA enhanced MRI and curative hepatic resection, subjects received full information about indications, risks, and alternatives and then signed the written informed consent. Acknowledgments We thank Liwen Bianji (Edanz) for editing the English language in the draft of this manuscript. Author Contributions Conceptualization, Zhiyuan Chen, Xiaohuan Li, and Yupin Liu; design, Zhiyuan Chen, Dongjing Zhou, and Yupin Liu; Resources, Zhiyuan Chen, Yan Zhang, and Yupin Liu; execution, Xiaohuan Li, Yu Zhang, Yiming Yang, Yu Yang, and Shuping Zhang; acquisition of data, Xiaohuan Li, Yu Zhang, Yiming Yang, Yan Zhang, and Yu Yang; Formal Analysis, Zhiyuan Chen, Xiaohuan Li, Yan Zhang, and Dongjing Zhou;; Writing \u2013 Original Draft, Zhiyuan Chen, Xiaohuan Li, Yu Zhang, Yiming Yang, Yan Zhang, Yu Yang, and Shuping Zhang; Writing \u2013 Review & Editing, Zhiyuan Chen, Dongjing Zhou, and Yupin Liu. All authors made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; took part in drafting the article or revising it critically for important intellectual content; agreed to submit to the current journal; gave final approval of the version to be published; and agree to be accountable for all aspects of the work. Funding This work was funded by the Traditional Chinese medicine research project of the Second Affiliated Hospital of Guangzhou University of Chinese Medicine (YN2019QL09, ZY2022YL06). Disclosure The authors report no conflicts of interest in this work. References 1. Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400(10360):1345\u20131362. doi:10.1016/S0140- 6736(22)01200-4 2. Calderaro J, Seraphin TP, Luedde T, Simon TG. Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma. J Hepatol. 2022;76(6):1348\u20131361. 3. Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77(6):1598\u20131606. doi:10.1016/j.jhep.2022.08.021 4. Erstad DJ, Tanabe KK. Prognostic and therapeutic implications of microvascular invasion in hepatocellular carcinoma. Ann Surg Oncol. 2019;26 (5):1474\u20131493. doi:10.1245/s10434-019-07227-9 5. Beaufr\u00e8re A, Caruso S, Calderaro J, et al. Gene expression signature as a surrogate marker of microvascular invasion on routine hepatocellular carcinoma biopsies. J Hepatol. 2022;76(2):343\u2013352. doi:10.1016/j.jhep.2021.09.034 6. Wu Y, Zhu M, Liu Y, Cao X, Zhang G, Yin L. Peritumoral imaging manifestations on Gd-EOB-DTPA-enhanced MRI for preoperative prediction of microvascular invasion in hepatocellular carcinoma: a systematic review and meta-analysis. Front Oncol. 2022;12:907076. doi:10.3389/ fonc.2022.907076 7. Hong SB, Choi SH, Kim SY, et al. MRI features for predicting microvascular invasion of hepatocellular carcinoma: a systematic review and meta-analysis. Liver Cancer. 2021;10(2):94\u2013106. doi:10.1159/000513704 8. Rhee H, Cho ES, Nahm JH, et al. Gadoxetic acid-enhanced MRI of macrotrabecular-massive hepatocellular carcinoma and its prognostic implications. J Hepatol. 2021;74(1):109\u2013121. doi:10.1016/j.jhep.2020.08.013 9. Kang HJ, Kim H, Lee DH, et al. Gadoxetate-enhanced MRI features of proliferative hepatocellular carcinoma are prognostic after surgery. Radiology. 2021;300(3):572\u2013582. doi:10.1148/radiol.2021204352 10. Elsayes KM, Kielar AZ, Chernyak V, et al. LI-RADS: a conceptual and historical review from its beginning to its recent integration into AASLD clinical practice guidance. J Hepatocell Carcinoma. 2019;6:49\u201369. doi:10.2147/JHC.S186239 Journal of Hepatocellular Carcinoma 2023:10 https://doi.org/10.2147/JHC.S422632 1607 DovePress Powered by TCPDF (www.tcpdf.org) Powered by TCPDF (www.tcpdf.org) Chen et al Dovepress 11. Kim WR, Mannalithara A, Heimbach JK, et al. MELD 3.0: the model for end-stage liver disease updated for the modern era. Gastroenterology. 2021;161(6):1887\u20131895.e4. doi:10.1053/j.gastro.2021.08.050 12. Benchoufi M, Matzner-Lober E, Molinari N, Jannot AS, Soyer P. Interobserver agreement issues in radiology. Diagn Interv Imaging. 2020;101 (10):639\u2013641. doi:10.1016/j.diii.2020.09.001 13. He T, Zou J, Sun K, et al. Global research status and frontiers on microvascular invasion of hepatocellular carcinoma: a bibliometric and visualized analysis. Front Oncol. 2022;12:1037145. doi:10.3389/fonc.2022.1037145 14. Bai S, Yang P, Xie Z, et al. Preoperative estimated risk of microvascular invasion is associated with prognostic differences following liver resection versus radiofrequency ablation for early hepatitis b virus-related hepatocellular carcinoma. Ann Surg Oncol. 2021;28(13):8174\u20138185. doi:10.1245/ s10434-021-09901-3 15. Lee S, Kang TW, Song KD, et al. Effect of microvascular invasion risk on early recurrence of hepatocellular carcinoma after surgery and radiofrequency ablation. Ann Surg. 2021;273(3):564\u2013571. doi:10.1097/SLA.0000000000003268 16. Meng XP, Tang TY, Ding ZM, et al. preoperative microvascular invasion prediction to assist in surgical plan for single hepatocellular carcinoma: better together with radiomics. Ann Surg Oncol. 2022;29(5):2960\u20132970. doi:10.1245/s10434-022-11346-1 17. Zhang X, Li J, Shen F, Lau WY. Significance of presence of microvascular invasion in specimens obtained after surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol. 2018;33(2):347\u2013354. doi:10.1111/jgh.13843 18. Zhang L, Yu X, Wei W, et al. Prediction of HCC microvascular invasion with gadobenate-enhanced MRI: correlation with pathology. Eur Radiol. 2020;30(10):5327\u20135336. doi:10.1007/s00330-020-06895-6 19. Jiang H, Wei H, Yang T, et al. VICT2 trait: prognostic alternative to peritumoral hepatobiliary phase hypointensity in HCC. Radiology. 2023;307 (2):e221835. doi:10.1148/radiol.221835 20. Kitao A, Matsui O, Zhang Y,"}], "doc_text": "MVI, microvascular invasion; Gd-EOB-DTPA, gadolinium ethoxybenzyl diethylene- triamine pentaacetic acid; OATP, organic anion-transporting polypeptide; HBP, hepatobiliary phase; WBC, white blood cell count; RBC, red blood cell count; HB, hemoglobin; PLT, platelets; PT, prothrombin time; INR, international normalized ratio of prothrombin; APTT, activated partial thromboplastin time; FIB, fibrinogen; AST, aspartate amino- transferase; ALT, alanine transaminase; ALB, albumin; GLB, globulin; ALP, alkaline phosphatase; GGT, gamma- glutamyl transferase; TBIL, total bilirubin; Cr, creatinine; AFP, alpha-fetoprotein; CTP, Child-Turcotte-Pugh stage; MELD, model for end-stage liver disease score; AASLD, American association for the study of liver disease; RFS, recurrence-free survival; ROC, receiver operating characteristic; AUROC, area under ROC curve; OR, odds ratio; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value; HR, hazard ratio. 1606 Journal of Hepatocellular Carcinoma 2023:10 https://doi.org/10.2147/JHC.S422632 DovePress Powered by TCPDF (www.tcpdf.org) Powered by TCPDF (www.tcpdf.org) Dovepress Chen et al Data Sharing Statement The datasets used and/or analyzed in this study are available from the corresponding authors on reasonable request. Ethics Approval and Informed Consent The studies involving human participants were reviewed and approved by the ethics committee of the Second Affiliated Hospital of Guangzhou University of Chinese Medicine (BE2022-226). The study was completed in accordance with the Declaration of Helsinki, and all patient data are treated confidentially. The requirement for written informed consent was waived by the Institutional Review Board in view of the retrospective observational nature of the research. Before Gd- EOB-DTPA enhanced MRI and curative hepatic resection, subjects received full information about indications, risks, and alternatives and then signed the written informed consent. Acknowledgments We thank Liwen Bianji (Edanz) for editing the English language in the draft of this manuscript. Author Contributions Conceptualization, Zhiyuan Chen, Xiaohuan Li, and Yupin Liu; design, Zhiyuan Chen, Dongjing Zhou, and Yupin Liu; Resources, Zhiyuan Chen, Yan Zhang, and Yupin Liu; execution, Xiaohuan Li, Yu Zhang, Yiming Yang, Yu Yang, and Shuping Zhang; acquisition of data, Xiaohuan Li, Yu Zhang, Yiming Yang, Yan Zhang, and Yu Yang; Formal Analysis, Zhiyuan Chen, Xiaohuan Li, Yan Zhang, and Dongjing Zhou;; Writing \u2013 Original Draft, Zhiyuan Chen, Xiaohuan Li, Yu Zhang, Yiming Yang, Yan Zhang, Yu Yang, and Shuping Zhang; Writing \u2013 Review & Editing, Zhiyuan Chen, Dongjing Zhou, and Yupin Liu. All authors made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; took part in drafting the article or revising it critically for important intellectual content; agreed to submit to the current journal; gave final approval of the version to be published; and agree to be accountable for all aspects of the work. Funding This work was funded by the Traditional Chinese medicine research project of the Second Affiliated Hospital of Guangzhou University of Chinese Medicine (YN2019QL09, ZY2022YL06). Disclosure The authors report no conflicts of interest in this work. References 1. Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400(10360):1345\u20131362. doi:10.1016/S0140- 6736(22)01200-4 2. Calderaro J, Seraphin TP, Luedde T, Simon TG. Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma. J Hepatol. 2022;76(6):1348\u20131361. 3. Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77(6):1598\u20131606. doi:10.1016/j.jhep.2022.08.021 4. Erstad DJ, Tanabe KK. Prognostic and therapeutic implications of microvascular invasion in hepatocellular carcinoma. Ann Surg Oncol. 2019;26 (5):1474\u20131493. doi:10.1245/s10434-019-07227-9 5. Beaufr\u00e8re A, Caruso S, Calderaro J, et al. Gene expression signature as a surrogate marker of microvascular invasion on routine hepatocellular carcinoma biopsies. J Hepatol. 2022;76(2):343\u2013352. doi:10.1016/j.jhep.2021.09.034 6. Wu Y, Zhu M, Liu Y, Cao X, Zhang G, Yin L. Peritumoral imaging manifestations on Gd-EOB-DTPA-enhanced MRI for preoperative prediction of microvascular invasion in hepatocellular carcinoma: a systematic review and meta-analysis. Front Oncol. 2022;12:907076. doi:10.3389/ fonc.2022.907076 7. Hong SB, Choi SH, Kim SY, et al. MRI features for predicting microvascular invasion of hepatocellular carcinoma: a systematic review and meta-analysis. Liver Cancer. 2021;10(2):94\u2013106. doi:10.1159/000513704 8. Rhee H, Cho ES, Nahm JH, et al. Gadoxetic acid-enhanced MRI of macrotrabecular-massive hepatocellular carcinoma and its prognostic implications. J Hepatol. 2021;74(1):109\u2013121. doi:10.1016/j.jhep.2020.08.013 9. Kang HJ, Kim H, Lee DH, et al. Gadoxetate-enhanced MRI features of proliferative hepatocellular carcinoma are prognostic after surgery. Radiology. 2021;300(3):572\u2013582. doi:10.1148/radiol.2021204352 10. Elsayes KM, Kielar AZ, Chernyak V, et al. LI-RADS: a conceptual and historical review from its beginning to its recent integration into AASLD clinical practice guidance. J Hepatocell Carcinoma. 2019;6:49\u201369. doi:10.2147/JHC.S186239 Journal of Hepatocellular Carcinoma 2023:10 https://doi.org/10.2147/JHC.S422632 1607 DovePress Powered by TCPDF (www.tcpdf.org) Powered by TCPDF (www.tcpdf.org) Chen et al Dovepress 11. Kim WR, Mannalithara A, Heimbach JK, et al. MELD 3.0: the model for end-stage liver disease updated for the modern era. Gastroenterology. 2021;161(6):1887\u20131895.e4. doi:10.1053/j.gastro.2021.08.050 12. Benchoufi M, Matzner-Lober E, Molinari N, Jannot AS, Soyer P. Interobserver agreement issues in radiology. Diagn Interv Imaging. 2020;101 (10):639\u2013641. doi:10.1016/j.diii.2020.09.001 13. He T, Zou J, Sun K, et al. Global research status and frontiers on microvascular invasion of hepatocellular carcinoma: a bibliometric and visualized analysis. Front Oncol. 2022;12:1037145. doi:10.3389/fonc.2022.1037145 14. Bai S, Yang P, Xie Z, et al. Preoperative estimated risk of microvascular invasion is associated with prognostic differences following liver resection versus radiofrequency ablation for early hepatitis b virus-related hepatocellular carcinoma. Ann Surg Oncol. 2021;28(13):8174\u20138185. doi:10.1245/ s10434-021-09901-3 15. Lee S, Kang TW, Song KD, et al. Effect of microvascular invasion risk on early recurrence of hepatocellular carcinoma after surgery and radiofrequency ablation. Ann Surg. 2021;273(3):564\u2013571. doi:10.1097/SLA.0000000000003268 16. Meng XP, Tang TY, Ding ZM, et al. preoperative microvascular invasion prediction to assist in surgical plan for single hepatocellular carcinoma: better together with radiomics. Ann Surg Oncol. 2022;29(5):2960\u20132970. doi:10.1245/s10434-022-11346-1 17. Zhang X, Li J, Shen F, Lau WY. Significance of presence of microvascular invasion in specimens obtained after surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol. 2018;33(2):347\u2013354. doi:10.1111/jgh.13843 18. Zhang L, Yu X, Wei W, et al. Prediction of HCC microvascular invasion with gadobenate-enhanced MRI: correlation with pathology. Eur Radiol. 2020;30(10):5327\u20135336. doi:10.1007/s00330-020-06895-6 19. Jiang H, Wei H, Yang T, et al. VICT2 trait: prognostic alternative to peritumoral hepatobiliary phase hypointensity in HCC. Radiology. 2023;307 (2):e221835. doi:10.1148/radiol.221835 20. Kitao A, Matsui O, Zhang Y,"}